Arax Advisory Partners
LYEL icon

Arax Advisory Partners’s Lyell Immunopharma LYEL Stock Holding History

Arax Advisory Partners’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5
Closed -$132 – 2609
2024
Q3 		$132 Hold
5
– – ﹤0.01% 2542
2024
Q2 		$138 Buy
+5
New +$238 ﹤0.01% 2468

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Arax Advisory Partners's LYEL Position: Q4 2024 in Review

Arax Advisory Partners sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 5 shares — an estimated $132 sold.

Arax Advisory Partners first reported a position in LYEL in Q2 2024 and held it in 2 quarters. The position peaked at $138 in Q2 2024. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Arax Advisory Partners reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Arax Advisory Partners sold 5 Lyell Immunopharma shares in Q4 2024, an estimated $132.
  • Arax Advisory Partners first reported a position in Lyell Immunopharma in Q2 2024 and held it in 2 quarters.
  • Arax Advisory Partners's Lyell Immunopharma position peaked at $138 in Q2 2024.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Arax Advisory Partners's 13F filing for Q4 2024, filed 5 Feb 2025.